Last reviewed · How we verify
Intranasal Drug
At a glance
| Generic name | Intranasal Drug |
|---|---|
| Also known as | Dexmedetomidine, Placebo |
| Sponsor | Auris Medical AG |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Fully Resorbable Sinus Drug-eluting Stents in Patients With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps After Surgery: A Prospective, Randomized Controlled Trial (NA)
- Safety and Feasibility of Intranasal Insulin in Patients With Spinal Cord Injury (PHASE1)
- Intranasal AAV9-PHP.eB Gene Therapy in Cerebral Palsy (CP) & Hypoxic Ischemic Encephalopathy (HIE)
- Directed Topical Drug Delivery for Treatment for PASC Hyposmia (PHASE2)
- A Study Evaluating the Safety, Tolerability and Pharmacokinetics of ASY202 in Healthy Adults (PHASE1)
- Intranasal Dexmedetomidine-esketamine Administration and Postoperative Pain in Pediatric Patients (PHASE4)
- Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study (PHASE2)
- A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intranasal Drug CI brief — competitive landscape report
- Intranasal Drug updates RSS · CI watch RSS
- Auris Medical AG portfolio CI